Lifestyle Medicine and HIV Care in Viet Nam: Cardiometabolic Health, Treatment Continuity, and Stigma-Free Care

Lifestyle Medicine and HIV Care in Viet Nam: Cardiometabolic Health, Treatment Continuity, and Stigma-Free Care

Primary category: Evidence & Clinical Practice

Secondary category: Lifestyle Medicine in Viet Nam

Article type: VLMA Perspective

Last reviewed: October 30, 2026

A person living with HIV attends a routine follow-up appointment and receives reassuring news: their viral load remains undetectable, and antiretroviral treatment is working. Yet the same visit reveals elevated blood pressure, increasing blood glucose, or abnormal cholesterol levels. These findings raise questions that go beyond controlling the infection.

Effective HIV treatment has transformed long-term health expectations. With sustained access to antiretroviral therapy, many people living with HIV can lead long and productive lives. As they grow older, however, cardiovascular disease, diabetes, kidney disease, and other chronic conditions become increasingly relevant to their care.

This creates an opportunity for evidence-based Lifestyle Medicine, but also requires a clear understanding of its limits. Healthy behaviors can support cardiovascular and metabolic health, physical functioning, and psychological well-being. They cannot replace antiretroviral therapy, eliminate every HIV-related health risk, or overcome barriers to healthcare through individual effort alone.

For healthcare professionals in Viet Nam, the challenge is to address these broader health needs while maintaining effective HIV treatment, protecting confidentiality, and ensuring that people receive appropriate care without stigma or discrimination.

Successful HIV Treatment Remains the Foundation

HIV is a viral infection that can progressively damage immune function when not appropriately treated. Antiretroviral therapy suppresses viral replication, supports immune recovery, and substantially reduces HIV-related illness and mortality.

The World Health Organization published updated recommendations on HIV clinical management on December 24, 2025, followed by a public announcement in January 2026. These recommendations address optimized antiretroviral regimens, prevention of vertical HIV transmission, and tuberculosis prevention among people living with HIV. [1]

Advances in treatment have improved the prospects for long-term health. However, there is currently no established, broadly applicable cure for HIV infection. No dietary pattern, exercise program, supplement, fasting regimen, or other lifestyle intervention has been demonstrated to replace effective antiretroviral therapy.

Maintaining viral suppression also has an important prevention benefit. The principle known as Undetectable = Untransmittable, or U=U, is supported by strong scientific evidence. People living with HIV who take effective antiretroviral therapy and maintain a viral load below 200 copies of HIV RNA per milliliter do not transmit HIV through sexual contact. [2]

This finding matters for clinical counseling, personal relationships, and efforts to reduce misconceptions that contribute to HIV-related stigma. However, U=U specifically concerns sexual transmission under the relevant conditions of sustained viral suppression. It does not mean that HIV has been cured, that treatment can be discontinued, or that all possible routes of transmission carry no risk. It also does not prevent other sexually transmitted infections.

People starting antiretroviral therapy need appropriate counseling about additional HIV prevention measures until viral suppression has been achieved and confirmed. Continued treatment and recommended viral load monitoring remain essential.

The longer-term challenge is therefore not to move beyond HIV treatment, but to build comprehensive healthcare around its continued effectiveness.

Cardiometabolic Health Matters Even When HIV Is Suppressed

Cardiovascular disease has become an important consideration in the long-term management of people living with HIV.

Many familiar risk factors remain relevant. Smoking, hypertension, diabetes, abnormal lipid levels, physical inactivity, and unhealthy dietary patterns contribute to cardiovascular disease, just as they do in people without HIV. However, cardiovascular risk in people living with HIV cannot always be explained by these factors alone.

HIV-associated immune activation and inflammation, previous or ongoing effects of the infection, and certain antiretroviral medications may also influence cardiovascular and metabolic health. Some people experience changes in body weight, insulin sensitivity, or lipid metabolism during treatment, although these effects vary considerably between individuals and treatment regimens.

Consequently, conventional cardiovascular risk prediction tools may underestimate risk in some people living with HIV.

The United States Department of Health and Human Services updated its HIV treatment guidance on October 27, 2026, recognizing HIV as a factor that increases the risk of atherosclerotic cardiovascular disease and providing updated recommendations for cardiovascular risk assessment and prevention. [4]

For healthcare professionals, these developments reinforce the importance of assessing cardiometabolic health alongside HIV-specific clinical outcomes.

A person with sustained viral suppression may still require appropriate evaluation of blood pressure, lipid levels, glucose regulation, kidney function, tobacco exposure, and other relevant risk factors. An undetectable viral load is an important treatment achievement, but it does not establish that every aspect of the person's health is equally well controlled.

Identifying an abnormal result is only the beginning. Elevated blood pressure may require confirmation and an appropriate treatment plan. Abnormal glucose measurements may need further investigation, while lipid disorders may warrant pharmacological management. The response should reflect the individual's clinical circumstances and applicable guidance.

Lifestyle Medicine can contribute to managing modifiable risk factors, but it should remain part of a broader approach that includes medication, specialist assessment, and follow-up when clinically indicated.

The 2026 Statin Recommendations: An Important Change in Prevention

An important development in 2026 illustrates why cardiovascular prevention in people living with HIV should not rely on lifestyle interventions alone.

In March 2026, the American College of Cardiology, American Heart Association, and collaborating professional societies published an updated guideline on the management of dyslipidemia. [3]

For people living with HIV aged 40–75 years who are receiving stable combination antiretroviral therapy, the guideline recommends statin treatment to reduce the risk of a first atherosclerotic cardiovascular event.

The recommendation was incorporated into the updated United States HIV treatment guidance on October 27, 2026. The HIV guideline panel endorsed initiating statin therapy for people living with HIV in this age group regardless of low-density lipoprotein cholesterol levels or estimated cardiovascular risk. [4]

This is an important change in primary cardiovascular prevention because HIV-associated risk may not be fully captured by conventional risk calculations.

Evidence from the REPRIEVE randomized clinical trial contributed substantially to this development.

Published in the New England Journal of Medicine in 2023, the trial enrolled 7,769 participants living with HIV who were receiving antiretroviral treatment and had low-to-moderate predicted cardiovascular risk. Over a median follow-up of 5.1 years, participants assigned to pitavastatin experienced approximately 35% fewer major adverse cardiovascular events relative to those assigned to placebo. [5]

The incidence of these events was 4.81 per 1,000 person-years in the pitavastatin group compared with 7.32 per 1,000 person-years in the placebo group. This distinction is important: the reported 35% reduction represents a relative reduction in risk, not a 35-percentage-point absolute reduction.

The trial also identified potential harms. Muscle-related symptoms were reported more frequently among participants receiving pitavastatin, and new diabetes diagnoses occurred in 5.3% of participants in the pitavastatin group compared with 4.0% in the placebo group.

These findings demonstrate the importance of considering both the potential benefits and adverse effects of preventive treatment.

They do not diminish the value of nutrition, physical activity, or tobacco cessation. Instead, they illustrate why effective cardiovascular prevention may require lifestyle-related interventions alongside pharmacological treatment.

For healthcare professionals in Viet Nam, an important distinction must be maintained. These are United States clinical recommendations. Their publication does not automatically establish equivalent prescribing requirements in Viet Nam or confirm that a particular statin is locally approved, available, reimbursed, or suitable for every patient.

Treatment decisions must consider individual clinical circumstances, contraindications, possible adverse effects, treatment preferences, and applicable Vietnamese professional and pharmaceutical requirements.

Drug interactions deserve particular attention. Certain antiretroviral regimens, especially those containing pharmacokinetic boosters, can interact with lipid-lowering medications. The choice of statin, its dose, and monitoring arrangements therefore require appropriate medication review.

Patients should not independently start statin treatment, discontinue prescribed medication, or modify antiretroviral regimens on the basis of international recommendations.

The broader lesson is that Lifestyle Medicine is most valuable when it complements effective medical treatment rather than being presented as an alternative to it.

Lifestyle Support Should Reflect Individual Health Needs

Nutrition, physical activity, sleep, stress management, tobacco cessation, and positive social relationships can all contribute to health. Their application in people living with HIV should nevertheless reflect the individual's clinical condition, treatment, and everyday circumstances.

Nutrition provides a useful example. A person with hypertension, diabetes, or abnormal cholesterol levels may benefit from dietary changes that support cardiometabolic health. Another person may experience poor appetite, gastrointestinal symptoms, unintended weight loss, or difficulty obtaining adequate food. These situations require different responses.

Advising everyone living with HIV to lose weight, eliminate particular food groups, or follow a restrictive diet would be inappropriate. Nutritional recommendations should consider metabolic health, food availability, personal preferences, treatment-related concerns, and the need to maintain adequate nutritional intake.

In Viet Nam, practical dietary counseling may involve working with familiar foods and household eating patterns rather than assuming that a dietary program developed elsewhere is suitable for everyone. Affordability, working schedules, and access to appropriate food can also influence which recommendations are realistic.

Physical activity can support cardiovascular fitness, metabolic health, functional capacity, and psychological well-being. However, exercise recommendations should reflect the person's physical condition, previous activity, symptoms, associated diseases, and personal goals. Someone with significant cardiovascular concerns, advanced illness, or substantial functional limitations may need individualized assessment before increasing exercise intensity.

The benefits of physical activity should also be considered beyond weight change. Improvements in fitness, daily functioning, and well-being may be meaningful even when body weight remains stable.

Tobacco cessation deserves particular attention because smoking contributes substantially to cardiovascular disease, respiratory illness, and several cancers. Effective cessation support may involve behavioral counseling and appropriate pharmacological treatment rather than brief advice alone.

Sleep difficulties and chronic stress can also affect daily functioning and quality of life. Where these coexist with depression, anxiety, substance use disorders, or other clinical conditions, further assessment and suitable treatment may be necessary.

The aim should not be to give every person the same list of lifestyle targets. It is to identify which health concerns matter most, determine what changes are supported by evidence, and agree on realistic steps that can be maintained.

An important scientific distinction should also be preserved. Evidence that a lifestyle intervention improves cardiovascular or metabolic risk factors in the general population may be relevant to HIV care, but it does not automatically demonstrate an effect on HIV-related clinical outcomes.

Lifestyle Medicine should support achievable changes without placing additional blame or unrealistic expectations on people managing a lifelong condition.

Treatment Continuity Is More Than Medication Adherence

Maintaining effective antiretroviral therapy requires more than remembering to take medication.

A person may understand the importance of treatment but still encounter difficulties attending appointments, obtaining medicines, or maintaining regular follow-up.

Employment schedules, transportation costs, relocation, financial uncertainty, family responsibilities, and concerns about privacy can all interfere with access to care. Treatment-related adverse effects, mental health conditions, substance use disorders, and previous negative experiences with healthcare services may create further barriers.

These difficulties should not automatically be interpreted as evidence that a patient lacks motivation or is unwilling to follow treatment recommendations.

The World Health Organization's September 2025 HIV service delivery guideline includes updated recommendations for interventions that support adherence to antiretroviral therapy. Its consolidated service delivery guideline, published on July 22, 2026, further emphasizes person-centered, integrated, and equitable healthcare services. [6,7]

These recommendations encourage healthcare systems to consider how continued treatment can remain practical and accessible for people with different needs.

Someone working irregular hours may benefit from more suitable appointment arrangements. A person moving to another province may need assistance transferring care without interrupting medication supply. Someone concerned about confidentiality may require a discreet communication method agreed upon with the healthcare team.

Follow-up systems also need to distinguish between identifying a missed appointment and successfully reconnecting someone to care.

Recording that a person missed an appointment provides useful information, but it does not establish whether they have resumed treatment or received the support needed to continue. A more meaningful process involves identifying the concern, providing appropriate assistance, arranging follow-up, and confirming whether the person has reconnected with healthcare.

These activities must respect privacy and applicable legal requirements. Contacting family members, employers, or community organizations without appropriate authorization or safeguards may expose sensitive information and cause harm.

Treatment continuity is therefore not solely an individual behavior. It is influenced by clinical care, service organization, access, and trust.

Mental Health, Social Support, and Stigma-Free Care

Some of the most significant concerns experienced by people living with HIV may not be immediately apparent during a routine consultation.

A person may worry that their diagnosis could become known to family members, colleagues, or employers. Another may have experienced discrimination or may avoid healthcare because of previous negative experiences.

Such concerns can affect whether someone feels comfortable discussing symptoms, medication difficulties, sexual health, psychological distress, or other sensitive matters.

Stigma can also arise within healthcare settings. Language that implies blame, unnecessary questioning about personal circumstances, assumptions about sexual behavior or substance use, and failures to protect confidentiality can undermine trust.

Respectful care should not depend on whether a patient has achieved perfect medication adherence, stopped smoking, or followed every lifestyle recommendation.

Mental health support is relevant to comprehensive HIV care, but it should not be assumed that every person living with HIV has psychological difficulties or requires specialist mental health treatment.

The World Health Organization's September 2025 guidance recommends integrating mental health care into HIV services, including appropriate assessment and management of depression, anxiety, and alcohol use disorders. [6]

Lifestyle-related approaches such as physical activity, adequate sleep, stress management, and supportive social relationships may contribute to psychological well-being. However, they do not replace evidence-based psychological or psychiatric treatment when clinically indicated.

Social support may also be valuable when it responds to needs identified by the individual. Depending on circumstances, this may include assistance with healthcare access, employment, food security, or connection to appropriate community resources.

Participation in peer groups or community activities should remain sensitive to personal preferences and privacy. A referral intended to provide support can cause harm if it discloses someone's HIV status without a lawful basis or appropriate authorization.

The Lifestyle Medicine Core Competencies: 2025 Update recognizes the importance of social determinants of health and health equity in the application of evidence-based Lifestyle Medicine. [8]

This principle is particularly relevant in HIV care. A person's ability to maintain treatment and adopt healthier behaviors is influenced by access to healthcare, social circumstances, financial resources, experiences of discrimination, and the support available to them.

Healthy behavior matters, but it cannot be separated from the conditions that make healthcare accessible, acceptable, and safe.

Integrating HIV Care With Chronic Disease Prevention

In September 2025, the World Health Organization recommended integrating care for hypertension, diabetes, and mental health conditions into HIV service delivery. The July 2026 consolidated guideline reinforced the importance of coordinated, person-centered services. [6,7]

The rationale is straightforward. People receiving long-term antiretroviral therapy may also develop chronic conditions that require regular assessment and treatment.

Integration does not mean that every HIV clinic must independently provide all specialist services. It means establishing appropriate ways to identify additional health needs, initiate management within authorized professional capacity, and coordinate referrals when necessary.

Consider a hypothetical adult receiving HIV care who has maintained viral suppression but has repeatedly elevated blood pressure.

The HIV treatment team may recognize the abnormal finding and arrange appropriate assessment. Depending on the healthcare setting and clinical responsibilities, hypertension management may be provided directly or through another authorized healthcare service.

Lifestyle counseling could address tobacco use, dietary patterns, physical activity, and other relevant risk factors. If medication is indicated, the treating clinician should also consider possible interactions with antiretroviral therapy.

The important issue is what happens after the initial finding. Has hypertension been confirmed? Has appropriate treatment or referral been arranged? Does the receiving clinician have the relevant medication history? Is there a plan for monitoring and follow-up?

These questions concern continuity and clinical coordination rather than simply whether lifestyle advice was provided.

Other needs may also require attention, including kidney disease, tuberculosis, viral hepatitis, selected cancers, and mental health conditions, depending on clinical indications and applicable guidelines.

Not every person requires every investigation or specialist consultation. Care should remain proportionate to individual risk, clinical findings, and the available evidence.

Effective integration depends on clear professional responsibilities, appropriate information sharing, and reliable follow-up rather than unnecessarily complicated service arrangements.

Viet Nam's 2026 HIV Clinical Quality Standards

An important development in Viet Nam occurred on September 18, 2026, when the Ministry of Health issued Decision No. 2956/QĐ-BYT, introducing the Clinical Quality Standards for HIV/AIDS Care and Treatment. [9]

The document contains 16 clinical quality standards and provides for pilot implementation at outpatient HIV treatment clinics during 2026–2028.

The implementation plan begins with selected facilities, followed by review, refinement, and proposed voluntary expansion before consideration of a finalized national framework. During the pilot, the standards are intended to support self-assessment, technical assistance, and quality improvement.

They should not be described as a mandatory national accreditation system for all healthcare facilities. Pilot assessment results are intended to guide improvement and should not be treated as an automatic basis for restricting clinical activities, ranking hospitals, or determining reimbursement.

Several standards are particularly relevant to comprehensive HIV care and the potential contribution of Lifestyle Medicine.

Standard 9 addresses support for treatment adherence, appointment reminders, and reconnection with people who miss scheduled visits. It includes individualized support for those at increased risk of treatment interruption, together with confidentiality safeguards during follow-up.

The standard goes beyond whether a reminder was sent. It also considers whether a person who missed an appointment was contacted appropriately and successfully reconnected with care. This is important because the effectiveness of follow-up depends on what happens after the initial contact.

Standard 11 addresses access to comprehensive healthcare, including nutritional, psychological, and social support. It recognizes that effective HIV care may involve needs extending beyond viral suppression and antiretroviral medication.

Standard 12 focuses on detecting noncommunicable diseases among people receiving HIV care. Its indicators cover relevant areas such as blood pressure, body weight, glucose regulation, kidney function, lipid disorders, and behavioral risk factors. The framework also considers whether abnormal findings lead to appropriate counseling, management, referral, and follow-up.

Standard 13 addresses confidentiality and protection against stigma and discrimination, while Standard 15 focuses on maintaining uninterrupted access to examination, counseling, testing, and treatment services.

Taken together, these standards provide a practical connection between HIV-specific treatment quality, chronic disease prevention, service continuity, and patient rights.

They also recognize that outpatient HIV services may need to collaborate with other healthcare providers rather than independently deliver every form of specialist care.

For example, an HIV clinic may identify a cardiovascular risk factor and provide appropriate health education while arranging referral for clinical management beyond its authorized capacity. The quality of that arrangement depends on whether the patient receives appropriate care and follow-up, not merely whether the referral was recorded.

For the Vietnam Lifestyle Medicine Alliance, the standards offer a timely Vietnamese reference for understanding how evidence-based lifestyle approaches may complement comprehensive HIV care.

However, they do not establish Lifestyle Medicine as a separate HIV treatment specialty or authorize VLMA or other organizations to deliver clinical services outside applicable professional and healthcare facility requirements.

Confidentiality and Professional Responsibilities in Viet Nam

Protecting confidentiality is essential in HIV care because inappropriate disclosure can affect personal relationships, employment, social participation, and willingness to seek healthcare.

Viet Nam's Law on HIV/AIDS Prevention and Control No. 64/2006/QH11, as amended by Law No. 71/2020/QH14, establishes protections against stigma and discrimination and regulates access to and disclosure of information concerning a person's HIV status. [11]

These protections apply alongside the broader legal responsibilities of healthcare practitioners and organizations.

The Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, provide additional requirements governing the processing and protection of personal data. [13,14]

For healthcare organizations, confidentiality requires practical safeguards rather than general assurances.

Patient information should be accessed according to authorized responsibilities. Information shared between healthcare professionals should have an appropriate legal basis and permitted purpose, with necessary safeguards and consent where required.

Appointment reminders, referral arrangements, and communication with other services should be designed to avoid unnecessary disclosure.

These considerations also apply to lifestyle-related education and community support.

A person may benefit from a nutrition program, exercise group, or community service without needing to disclose their HIV status to everyone involved in delivering that activity.

Similarly, educational materials and professional discussions should not contain identifiable patient information unless applicable consent, confidentiality, and data protection requirements have been satisfied.

For professional educational publications, hypothetical scenarios are generally preferable when identifiable patient accounts are unnecessary.

Clinical responsibilities must remain equally clear.

The Law on Medical Examination and Treatment No. 15/2023/QH15, as amended, together with relevant implementing regulations and HIV-specific professional guidance, establishes requirements concerning healthcare practitioners, facilities, treatment responsibilities, and patient rights. [10,12]

Lifestyle-related education does not independently authorize someone to diagnose HIV-related conditions, prescribe medication, modify antiretroviral regimens, or provide regulated clinical services outside their lawful professional scope.

International recommendations may inform clinical understanding, but their inclusion in professional education does not automatically make them legally binding Vietnamese treatment requirements.

These distinctions allow professional collaboration to support better healthcare while maintaining appropriate accountability and protecting patients' rights.

What Better HIV Care Should Achieve

Healthcare organizations may record how many people receiving HIV care underwent blood pressure screening, received nutritional counseling, or attended a health education session.

These figures can describe service delivery, but they do not necessarily establish whether care has improved.

The more important question is whether clinically relevant needs were identified and addressed while HIV treatment remained effective and uninterrupted.

An abnormal glucose result may require further assessment. A person referred for hypertension management may need confirmation that the referral resulted in appropriate care. Someone experiencing difficulty obtaining antiretroviral medication may require assistance before treatment is interrupted.

Viral suppression and continued engagement in HIV care remain central outcomes. Cardiometabolic monitoring, psychological support, and patient experience should complement these priorities rather than compete with them.

Viet Nam's 2026 clinical quality standards provide a practical framework for considering these issues within the defined pilot setting.

Their relevance extends beyond counting activities. They encourage attention to the reliability of clinical processes, appropriate responses to abnormal findings, continuity of treatment, and protection of patient confidentiality.

Additional data collection should nevertheless remain proportionate to the service's responsibilities. Monitoring needs a clear purpose, appropriate safeguards, and a practical connection to improving care.

Quality improvement should make healthcare safer and more effective without creating unnecessary reporting burdens or additional barriers for people receiving treatment.

The Role and Limits of Lifestyle Medicine

Lifestyle Medicine offers evidence-based approaches to improving health through nutrition, physical activity, restorative sleep, stress management, avoidance of harmful substances, and positive social connections.

In people living with HIV, these approaches may contribute to general health, cardiovascular and metabolic risk management, physical functioning, psychological well-being, and quality of life.

However, the strength of evidence differs across interventions and outcomes.

Benefits demonstrated for cardiovascular or metabolic risk factors should not be presented as proof that a lifestyle intervention directly suppresses HIV, restores immune function, or prevents every HIV-related complication.

There is no established evidence that a particular lifestyle program cures HIV or allows prescribed antiretroviral therapy to be stopped safely.

Lifestyle support should also not delay necessary diagnostic investigations, pharmacological prevention, specialist assessment, or other medical treatment.

Its appropriate contribution is complementary. It can help healthcare professionals understand the daily circumstances influencing health and work with people to identify clinically relevant, realistic, and sustainable changes.

This requires collaboration with the professionals responsible for HIV treatment and any associated medical conditions.

For the Vietnam Lifestyle Medicine Alliance (VLMA), HIV care is a relevant area for professional education and scientific knowledge exchange.

The relationship between long-term antiretroviral therapy, cardiometabolic risk, behavior change, mental health, treatment continuity, and social circumstances offers opportunities to examine how evidence-based Lifestyle Medicine can complement established clinical care.

Potential educational topics include interpreting international cardiovascular prevention recommendations, understanding lifestyle-related risk factors among people receiving HIV treatment, supporting sustainable health behaviors, and recognizing the importance of stigma-free care.

Such activities require appropriate professional expertise and careful consideration of Vietnamese clinical and regulatory requirements.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. Its intended role is to support evidence-based Lifestyle Medicine through professional education, capability development, scientific knowledge exchange, and responsible collaboration.

VLMA does not independently diagnose or treat HIV, prescribe antiretroviral or cardiovascular medication, operate an HIV clinical service, or manage individual patients.

Its contribution is to strengthen professional understanding without creating expectations that lifestyle education replaces clinical qualifications, authorized healthcare services, or established HIV treatment guidance.

From Viral Suppression to Long-Term Health

The success of antiretroviral therapy has made long-term health an increasingly important part of HIV care.

For someone whose viral load remains suppressed, the next concern may be blood pressure, diabetes risk, smoking cessation, or an emerging problem with kidney function. Another person may struggle to maintain treatment while changing employment or moving to another province. Someone else may need psychological support or reassurance that their medical information will remain confidential.

These needs differ, but they belong within the same understanding of comprehensive healthcare.

Recent World Health Organization recommendations, the 2026 United States cardiovascular prevention guidance, and Viet Nam's clinical quality standards all reinforce the importance of looking beyond viral suppression while keeping effective HIV treatment at the center of care.

Lifestyle Medicine can contribute when its interventions are evidence-based, clinically appropriate, and responsive to individual circumstances. Its purpose should not be to replace antiretroviral therapy with healthier habits or place additional responsibility on individuals for conditions they cannot fully control.

The opportunity is to support long-term health while protecting the treatment continuity, dignity, confidentiality, and trust on which successful HIV care depends.

For healthcare professionals in Viet Nam, comprehensive HIV care means paying attention to chronic disease risks, the reliability of healthcare services, and the experience of people receiving treatment. Lifestyle Medicine has a role in that broader approach, provided it remains grounded in evidence and integrated with appropriate medical care.

Selected References

1. World Health Organization. WHO Updated Recommendations on HIV Clinical Management: Recommendations for a Public Health Approach. Geneva: World Health Organization; December 24, 2025. Public announcement January 2026.

2. Centers for Disease Control and Prevention. Undetectable = Untransmittable. August 19, 2024.

3. American College of Cardiology, American Heart Association, and collaborating professional organizations. 2026 Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026. DOI: 10.1016/j.jacc.2025.11.016.

4. United States Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV: Cardiovascular Complications in People With HIV. Updated October 27, 2026.

5. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. New England Journal of Medicine. 2023;389:687–699. DOI: 10.1056/NEJMoa2304146.

6. World Health Organization. WHO Guideline on HIV Service Delivery: Updated Guidance on the Integration of Diabetes, Hypertension and Mental Health Services, and Interventions to Support Adherence to Antiretroviral Therapy. Geneva: World Health Organization; September 1, 2025.

7. World Health Organization. Consolidated HIV Guidelines: Service Delivery. Geneva: World Health Organization; July 22, 2026. ISBN: 978-92-4-012423-3.

8. Rea BL, Cheema S, Lanza S, et al. Lifestyle Medicine Core Competencies: 2025 Update. American Journal of Lifestyle Medicine. 2026;20(3):443–451. First published online October 28, 2025. DOI: 10.1177/15598276251379821.

9. Ministry of Health of Viet Nam. Decision No. 2956/QĐ-BYT Issuing the Clinical Quality Standards for HIV/AIDS Care and Treatment. September 18, 2026. Pilot implementation at outpatient HIV treatment clinics during 2026–2028.

10. Ministry of Health of Viet Nam. Decision No. 5968/QĐ-BYT Issuing the Guidelines for HIV/AIDS Treatment and Care. December 31, 2021.

11. National Assembly of Viet Nam. Law on HIV/AIDS Prevention and Control No. 64/2006/QH11. June 29, 2006, as amended by Law No. 71/2020/QH14 dated November 16, 2020.

12. National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. January 9, 2023. Effective January 1, 2024, as amended.

13. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025. Effective January 1, 2026.

14. Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing Certain Articles and Measures for Implementing the Law on Personal Data Protection. December 31, 2025. Effective January 1, 2026.

Editorial and Professional Scope Note

This article presents the professional perspective of the Vietnam Lifestyle Medicine Alliance on the contribution and limitations of evidence-based Lifestyle Medicine in comprehensive HIV care, including cardiometabolic health, treatment continuity, mental health, and stigma-free healthcare. It reflects scientific and regulatory information reviewed as of October 30, 2026.

The article is intended for professional information, education, and scientific knowledge exchange. It does not constitute an official clinical practice guideline, individualized medical advice, a diagnostic or treatment protocol, a medication prescription, or an authoritative interpretation of Vietnamese law. The patient scenarios are hypothetical and do not describe actual VLMA clinical activities or identifiable patients.

Lifestyle interventions do not cure HIV and must not replace, delay, or interrupt prescribed antiretroviral therapy, appropriate clinical monitoring, or other necessary medical treatment.

References to international recommendations, including United States guidance on statin therapy and cardiovascular prevention, do not imply their automatic adoption as Vietnamese clinical standards or establish the regulatory approval, availability, reimbursement, or suitability of particular medicines in Viet Nam.

The discussion of Decision No. 2956/QĐ-BYT reflects its defined pilot application during 2026–2028 and does not imply that the standards constitute a mandatory national healthcare accreditation system.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It is not a licensed HIV treatment facility, medical licensing authority, or healthcare accreditation organization. VLMA does not independently diagnose or treat HIV, prescribe antiretroviral or cardiovascular medications, or provide individualized clinical follow-up.

Clinical assessment, treatment, prescribing, referral, and follow-up must remain under the responsibility of appropriately authorized healthcare professionals and facilities acting within their lawful scopes of practice.

Patient information, including HIV status, must be handled in accordance with applicable confidentiality, consent, and personal data protection requirements.

International guidelines and scientific publications are referenced for educational purposes. Their inclusion does not imply that VLMA has formally adopted, clinically implemented, evaluated, validated, or certified any HIV care or Lifestyle Medicine intervention discussed in this article.